Oncoceutics' Series A - II Round

Oncoceutics raised a round of funding on October 06, 2015. Investors include Spring Mountain Capital.

Oncoceutics is a clinical-stage drug discovery and development company targeting the most potent suppressor pathways in human cancer. The first lead compound to result from this program is ONC201, a s…

Articles about Oncoceutics' Series A - II Round: